As the coronavirus started to spread in 2020, industry watchers hoped the biopharma sector would pull through and shore up both the IPO market and venture capital investment.
Private investment in the biopharma industry had been trending generally upward, with dips in 2016 and 2019. The second trough followed a record-setting 2018, in which biopharma companies—those developing therapeutics for human disease—raked in a total of $17.9 billion.
Image: https://www.fiercebiotech.com
